Wearable Continuous Glucose Monitoring Devices Market to Reach US$ 32.48 Billion by 2033 as Real-Time Diabetes Management Moves Toward Continuous, Sensor-Based Care

Exclusive Market Analysis | Healthcare AI & Medical Technology

The global wearable continuous glucose monitors market reached US$ 12.20 billion in 2024 and is expected to reach US$ 32.48 billion by 2033, growing at a 10.3% CAGR during 2025-2033, according to DataM Intelligence. The market is expanding as wearable continuous glucose monitors reshape diabetes care through real-time glucose data, remote monitoring, mobile app integration, automated alerts and preventive health adoption. What began as a diabetes monitoring device category is now becoming a connected metabolic monitoring platform, linking patients, caregivers, clinicians, payers and digital health ecosystems around continuous patient-data intelligence.

Request Executive Sample | Market Intelligence: https://www.datamintelligence.com/download-sample/wearable-continuous-glucose-monitors-market?kailas

Key Developments in CGM Product Launches, Sensor Upgrades, Regulatory Clearances and Partnerships

1. Dexcom announced in June 2026 that the FDA cleared its Stelo Glucose Biosensor System for over-the-counter pediatric use in people aged two years and older who do not use insulin. The FDA stated that Stelo is an integrated CGM that uses a wearable sensor and compatible app to measure, record, analyze and display glucose values.

2. Dexcom also reported results from its 2026 CONNECT randomized controlled trial, showing that Dexcom G7 use in adults with Type 2 diabetes not using insulin led to clinically and statistically significant A1C reduction and improved time in range compared with routine care. This is commercially important because it supports CGM expansion into a much larger Type 2 diabetes population.

3. Abbott secured CE Mark in May 2026 for Libre Duo and Libre Duo 10 Day, described by the company as the world's first dual glucose sensing technology for people with diabetes. The system is designed to continuously measure glucose and levels every minute and integrate with Abbott's Libre digital health ecosystem.

4. Medtronic announced in February 2026 that Medicare and Medicare Advantage beneficiaries could access the MiniMed 780G system with the Instinct sensor, made by Abbott, while also noting FDA clearances that expanded use of the MiniMed 780G system for insulin-requiring Type 2 diabetes. This development highlights the convergence of CGM, automated insulin delivery and payer access.

5. Senseonics received CE Mark approval in January 2026 for Eversense 365, its one-year implantable CGM system, and later announced the first European launch of the product in April 2026. The company positioned Eversense 365 around longer wear duration, fewer sensor-change interruptions and a differentiated implantable approach.

Connected-Care Shift: CGM Becomes a Metabolic Data Platform

A wearable glucose monitor continuously tracks glucose levels through a sensor worn on or under the skin, helping users understand glucose movement throughout the day instead of relying only on periodic fingerstick readings. In modern connected care, this data can be viewed through mobile apps, shared with caregivers, reviewed by clinicians and combined with insulin dosing, food, exercise, sleep and stress signals.

This shift is changing the commercial identity of the wearable continuous glucose monitors market. CGM is no longer only a device sale; it is a recurring sensor, app, analytics and care-navigation ecosystem. That makes interoperability, payer coverage, data privacy, sensor accuracy and clinical evidence central to market competition.

Growth Drivers: Diabetes Burden, Miniaturized Sensors and Remote Care

Rising diabetes prevalence remains the core demand driver. The International Diabetes Federation estimates that 589 million adults aged 20-79 were living with diabetes worldwide in 2024, with the number projected to rise to 853 million by 2050. This creates sustained demand for better diabetes monitoring devices that can support early intervention, treatment adjustment and long-term disease management.

Sensor miniaturization is another major driver. Smaller, longer-wear sensors reduce patient burden and make CGM more practical for everyday use. App ecosystems are equally important because users increasingly expect glucose data to be translated into simple, personalized and actionable insights.

Remote patient monitoring is also strengthening adoption. CGM can help clinicians and care teams identify patterns between visits, support hospital-at-home models and reduce dependence on episodic glucose checks. Medicare.gov states that Medicare may cover continuous glucose monitors and related supplies for eligible people with diabetes who meet coverage conditions, reinforcing the role of payer policy in adoption.

Request a Customized Report According to Your Business Strategy: https://www.datamintelligence.com/customize/wearable-continuous-glucose-monitors-market?kailas

Detailed Segment Analysis
Sensors Segment: The Revenue Engine of Wearable CGM

DataM Intelligence segments the market by component into receiver or display device, sensors, transmitters and others, and states that sensors accounted for 71.4% of market share in 2024. Sensors dominate because they are the core consumable element of a CGM system and must be replaced at regular intervals depending on product design.

The sensor segment is strategically important because it determines accuracy, wear duration, user comfort, replacement frequency and long-term cost of care. A better sensor can improve adherence, reduce false alerts, support automated insulin delivery and enable broader use in preventive health. Longer wear products, such as 15-day, 365-day or dual-analyte systems, show how competition is shifting toward fewer disruptions and richer metabolic signals.

Type 2 Diabetes Segment: The Largest Expansion Opportunity

DataM segments the market by indication into Type 1 diabetes and Type 2 diabetes. Type 1 diabetes remains a high-value clinical base because CGM is closely tied to insulin therapy, hypoglycemia prevention and automated insulin delivery. However, Type 2 diabetes is becoming the larger market-expansion opportunity because many people with Type 2 diabetes are not yet using continuous data to guide daily behavior or therapy decisions.

Dexcom's CONNECT study is particularly relevant to this segment because it focused on adults with Type 2 diabetes not using insulin and showed improved A1C and time-in-range outcomes with Dexcom G7. Abbott's FreeDM2 trial update also supports the Type 2 opportunity by showing better glucose outcomes for people using FreeStyle Libre technology compared with traditional fingersticks in a basal-insulin Type 2 population.

Adults and Geriatrics Segment: Practical Demand from Chronic Disease Management

DataM also segments the market by age group into children, adults and geriatrics. Adults form the largest practical adoption base because Type 2 diabetes, prediabetes and lifestyle-related metabolic risk are most concentrated in adult populations. Geriatric users are also important because diabetes management in older adults often involves multiple medications, hypoglycemia risk, caregiver support and payer coverage considerations.

For this segment, usability matters as much as sensor performance. Clear apps, caregiver sharing, simple insertion, reimbursement support and fewer device-change events can influence adoption. Implantable and longer-wear CGMs are relevant because older users may value reduced replacement frequency and more dependable monitoring continuity.

Disruption: Access, Privacy, Wellness Claims and Interoperability

The market faces four major disruptions. First, payer access remains uneven. Even when CGM is clinically useful, coverage rules, documentation requirements and patient affordability can limit use. CMS notes that glucose monitor claims face documentation-related denial risks, showing that reimbursement execution remains a real operational issue.

Second, data privacy is becoming more important as CGM moves into mobile apps, coaching platforms and caregiver-sharing tools. Third, non-diabetic wellness use creates opportunity but also raises concerns around claims, user interpretation and responsible guidance. Fourth, interoperability is becoming a procurement requirement as CGM data increasingly connects with insulin pumps, EHRs, digital therapeutics and remote-care platforms.

Regional Outlook: USA, Japan, Germany and South Korea

The USA market leads adoption because it combines high diabetes burden, FDA-cleared products, Medicare coverage pathways, advanced digital health infrastructure and strong competition among Dexcom, Abbott, Medtronic and Senseonics. OTC CGM clearances and Type 2 diabetes clinical evidence are expanding the market beyond traditional intensive-insulin users.

Japan is a high-potential market because its regulated medical device environment, aging population and advanced healthcare infrastructure create demand for connected chronic disease management. PMDA records for Dexcom G7 show the system includes a sensor, app or monitor, Bluetooth communication and mobile-device connectivity, supporting Japan's relevance for app-connected CGM adoption.

Germany remains important because real-time CGM is recognized within statutory health insurance for insulin-dependent diabetes under the Federal Joint Committee framework, while South Korea is becoming more relevant as MFDS maintains medical-device approval and certificate-verification pathways and Dexcom has announced planned Stelo availability there.

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=wearable-continuous-glucose-monitors-market?kailas

Competitive Landscape and Official Company Profiles

DataM Intelligence lists major players including Dexcom, Abbott, Medtronic, Senseonics, F. Hoffmann-La Roche and Afon Technology.

Dexcom is positioned around real-time glucose biosensing, CGM apps, diabetes decision support and metabolic health expansion. Its 2026 Stelo pediatric clearance, CONNECT study and reimagined Stelo app strategy strengthen its role in Type 2 diabetes, preventive care and consumer-accessible glucose tracking.

Abbott competes through the FreeStyle Libre ecosystem, broad CGM adoption and connected biowearables. Its 2026 Libre Duo CE Mark adds monitoring to glucose sensing, expanding the value proposition from daily glucose control toward earlier DKA risk visibility and richer metabolic monitoring.

Medtronic brings CGM into automated insulin delivery, smart dosing and payer-access pathways. Its 2026 MiniMed 780G updates show how CGM is becoming part of full-stack diabetes technology rather than a standalone monitoring device.

Senseonics offers a differentiated long-term implantable CGM model. Its Eversense 365 approval and European launch demonstrate a competitive strategy centered on reducing sensor-change burden and improving monitoring continuity over a full year.

Outlook: Patient-Data Intelligence Defines the Next CGM Cycle

The next phase of the wearable continuous glucose monitors market will be defined by patient-data intelligence. The strongest platforms will not only measure glucose; they will convert continuous metabolic data into trusted insights for therapy adjustment, lifestyle change, caregiver support, remote monitoring and preventive health.

As the CGM market expands across Type 2 diabetes, hospital-at-home care, pregnancy-related glucose monitoring and broader metabolic health, the competitive advantage will shift toward evidence, usability, interoperability, payer access and responsible data governance. In connected diabetes care, wearable CGM is becoming one of the most commercially important bridges between medical devices, digital health and personalized prevention.

Read Exclusive Report Description: https://www.datamintelligence.com/research-report/wearable-continuous-glucose-monitors-market

Contact:
Fabian Mathew
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: fabian@datamintelligence.com

About DataM Intelligence
DataM Intelligence is a global market research and business intelligence firm delivering actionable insights across healthcare, pharmaceuticals, chemicals, energy, technology, food, and industrial sectors. Through syndicated reports, custom research, consulting, and competitive intelligence services, the company helps organizations identify growth opportunities, navigate market challenges, and make informed strategic decisions in over 50+ countries worldwide.

This release was published on openPR.